why is tirzepatide no longer available A Major GLP-1 Drug Shortage Over. Some Patients Aren't Celebrating What to Expect After Starting
Description
Feldman and colleagues in 2025, recapitulated these findingsin patients 40 years or older with T2D and active COPD, GLP-1RAs and SGLT-2 inhibitors, but not DDP-4 inhibitors, reduced the risk of moderate or severe COPD exacerbations
Current injectable options offer considerable relief and weight loss support
GLP-1 agonist use was associated with a 5.5 3.2-point reduction in BMI compared to 2.9 2.4 amongst controls ( p = 0.026)
Cell Biol Toxicol [Internet]
